The Targeted Pulse: Targeted Therapies and Treatment Optimization

This week in oncology, the landscape shifted across several fronts, from a pivotal study challenging long-held surgical norms in breast cancer to promising new regulatory milestones for lung and ovarian cancers. Here is your summary of the top 5 stories in clinical oncology.

1. Surveillance vs. Mastectomy: No Survival Advantage for BRCA1/2 Carriers

A recent study has challenged the clinical assumption that risk-reducing mastectomy (RRM) provides a survival benefit over intensive surveillance for patients with BRCA1 or BRCA2 mutations. The data suggests that while RRM significantly reduces the risk of developing breast cancer, it does not necessarily translate to a significant overall survival advantage when compared to high-intensity surveillance (including annual MRIs).

Why it matters: This finding empowers patients and clinicians to have more nuanced discussions regarding quality of life. For many carriers, intensive monitoring may be a safe and effective alternative to major surgery without compromising long-term survival.

2. Neladalkib NDA Submitted for Advanced ALK+ NSCLC

Nuvalent has officially submitted a new drug application (NDA) to the FDA for neladalkib, a potent, brain-penetrant, ALK-selective inhibitor. The application seeks approval for the treatment of patients with advanced ALK-positive non–small cell lung cancer (NSCLC) who have been previously treated with 1 or more ALK TKIs.

The Impact: Neladalkib is specifically designed to overcome common resistance mutations, such as G1202R, which often render earlier-generation inhibitors ineffective. If approved, it could provide a much-needed next-line therapy for patients who have exhausted current standard-of-care options.

3. Reduced Lymphodepletion Shows Promise in TIL Therapy for Melanoma

Tumor-infiltrating lymphocyte (TIL) therapy is traditionally preceded by intensive, high-dose lymphodepletion, which can carry significant toxicity. New data suggest that a "reduced" lymphodepletion regimen may still offer efficacy for patients with high-risk melanoma.

The Takeaway: By lowering the intensity of the preconditioning regimen, clinicians may be able to reduce the duration of hospital stays and the severity of adverse events, making TIL therapy a more viable option for a broader range of patients who might not tolerate standard "full-dose" chemotherapy.

4. FDA Grants Fast Track Designation to CTIM-76 for Ovarian Cancer

The FDA has granted fast track designation to CTIM-76, an investigational CLDN6-targeted antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. CLDN6 is a protein highly expressed in several solid tumors but largely absent in healthy adult tissue, making it an ideal target.

The Potential: Platinum-resistant ovarian cancer remains one of the most difficult-to-treat malignancies in gynecology. The fast track designation will accelerate the development and review process, potentially bringing this targeted ADC to the clinic sooner.

5. Statins May Augment Outcomes in CD19 CAR T-Cell Therapy

In a fascinating look at drug repurposing and metabolic modulation, new research indicates that the use of statins (common cholesterol-lowering medications) may be associated with improved clinical outcomes in patients receiving CD19 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma.

The Mechanism: While the exact biological pathway is still being studied, researchers believe statins may mitigate certain inflammatory responses or modulate the tumor microenvironment to allow CAR T cells to function more effectively. This suggests that a low-cost, existing medication could serve as a valuable adjunct to one of the most expensive therapies in oncology.

Subscribe to The Targeted Pulse newsletter on LinkedIn—subscribers get early access to every edition!